Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Acova; Arganova; Argatra; Argipidine; Da Bei; DK 7419; Exembol; GN 1600; MCI-9038; MD 805; Novastan; OM 805; Slonnon

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitsubishi Chemical
  • Developer Correvio Pharma; Daiichi Sankyo Company; Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Europe; Novartis; University of Texas Health Science Center at Houston
  • Class Antithrombotics; Carboxylic acids; Pipecolic acids; Piperidines; Quinolines; Small molecules; Sulfones
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Arterial thrombosis; Heparin-induced thrombocytopenia and thrombosis syndrome; Peripheral arterial occlusive disorders; Stroke
  • Registered Intracranial thrombosis
  • Discontinued Myocardial infarction; Unstable angina pectoris

Most Recent Events

  • 15 May 2018 Cardiome Pharma is now called Correvio Pharma
  • 20 Dec 2017 Registered for Cerebral thrombosis in China (IV) (9231744; 9231270)
  • 23 Feb 2017 Preregistration for Cerebral thrombosis in China (IV) (Mitsubishi Tanabe Pharma Corporation pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top